Evaluate NTLA stock safety — financial health, volatility, institutional backing, and risk factors.

What are the risks of investing in NTLA? | Glauxie AI

Q: What are the risks of investing in NTLA?

Intellia Therapeutics, Inc. (NTLA) operates in the Biotechnology industry (Healthcare sector). The company is led by CEO John Leonard. Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the... Employees: 50,000.

Q: How much debt does NTLA have?

Review NTLA total debt, debt-to-equity ratio, interest coverage, and leverage trends.

Q: Is NTLA a good long-term investment?

Evaluate NTLA as a long-term investment using fundamental scores, growth metrics, and risk assessment.

What are the risks of investing in NTLA?

🦉

Intellia Therapeutics, Inc. (NTLA)

Company Overview

Sector / IndustryHealthcare / Biotechnology

CEOJohn Leonard

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well...

Key Executives

Name	Title
Birgit Schultes	Executive VP & Chief Scientific Officer
David Lebwohl	Executive Vice President & Chief Medical Officer
Derrick J. Rossi	Founder and Member of Scientific Advisor Board
Edward J. Dulac	Executive Vice President, Chief Financial Officer and Treasurer
Eliana Clark	Executive VP & Chief Technical Officer
Erik J. Sontheimer	Founder and Member of Scientific Advisor Board

Financial Health

Risk Assessment

Weather Score0/100

RegimeN/A

NTLA Profile Financials

Is NTLA stock safe? How much debt does NTLA have? Is NTLA a good long-term investment?